Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats
Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized c...
Gespeichert in:
Veröffentlicht in: | Journal of veterinary pharmacology and therapeutics 2017-12, Vol.40 (6), p.e11 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 6 |
container_start_page | e11 |
container_title | Journal of veterinary pharmacology and therapeutics |
container_volume | 40 |
creator | Lebkowska-Wieruszewska, B De Vito, V Owen, H Poapholatep, A Giorgi, M |
description | Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr
kg
, range 120-326 ml hr
kg
) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species. |
doi_str_mv | 10.1111/jvp.12414 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_jvp_12414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28459136</sourcerecordid><originalsourceid>FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqWw4AeQt0gktR0nsZcIlYJUiS66j6a2E9zmJdtU4iP4Z1wKzGYWc-6V5iB0S0lK48x3hzGljFN-hqY0K_KECZGfoymhnCRlKbIJuvJ-RwjJBKWXaMIEz2Ukp-hr_Q6uAzXsbW-CVR4PNW4cjHZ00IcHDNib1qhgDwYv1pjj0Q0-QNNCr22P18sFZtgZZcYwOBwj0Ay99cdkHYyLx66Z7xs8OGjjWWObHlIMurNHykGwQ-9xbFIQ_DW6qKH15uZ3z9DmebF5eklWb8vXp8dVomRZJDU1WhApVS4UJUpxgJzmhkvJpC45J7Iw28xopmtgUG5zJZkAmYExqiSiyGbo_lSr4i_emboane3AfVaUVEejVTRa_RiN7N2JHT-2ndH_5J_C7BvtLXKX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lebkowska-Wieruszewska, B ; De Vito, V ; Owen, H ; Poapholatep, A ; Giorgi, M</creator><creatorcontrib>Lebkowska-Wieruszewska, B ; De Vito, V ; Owen, H ; Poapholatep, A ; Giorgi, M</creatorcontrib><description>Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr
kg
, range 120-326 ml hr
kg
) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species.</description><identifier>ISSN: 0140-7783</identifier><identifier>EISSN: 1365-2885</identifier><identifier>DOI: 10.1111/jvp.12414</identifier><identifier>PMID: 28459136</identifier><language>eng</language><publisher>England</publisher><subject>Administration, Oral ; Animals ; Cats ; Cross-Over Studies ; Injections, Intravenous - veterinary ; Male ; Receptors, Prostaglandin E, EP4 Subtype - antagonists & inhibitors ; Sulfonylurea Compounds - administration & dosage ; Sulfonylurea Compounds - blood ; Sulfonylurea Compounds - pharmacokinetics</subject><ispartof>Journal of veterinary pharmacology and therapeutics, 2017-12, Vol.40 (6), p.e11</ispartof><rights>2017 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</citedby><cites>FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</cites><orcidid>0000-0003-3657-4703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28459136$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lebkowska-Wieruszewska, B</creatorcontrib><creatorcontrib>De Vito, V</creatorcontrib><creatorcontrib>Owen, H</creatorcontrib><creatorcontrib>Poapholatep, A</creatorcontrib><creatorcontrib>Giorgi, M</creatorcontrib><title>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</title><title>Journal of veterinary pharmacology and therapeutics</title><addtitle>J Vet Pharmacol Ther</addtitle><description>Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr
kg
, range 120-326 ml hr
kg
) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Cats</subject><subject>Cross-Over Studies</subject><subject>Injections, Intravenous - veterinary</subject><subject>Male</subject><subject>Receptors, Prostaglandin E, EP4 Subtype - antagonists & inhibitors</subject><subject>Sulfonylurea Compounds - administration & dosage</subject><subject>Sulfonylurea Compounds - blood</subject><subject>Sulfonylurea Compounds - pharmacokinetics</subject><issn>0140-7783</issn><issn>1365-2885</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtOwzAQRS0EoqWw4AeQt0gktR0nsZcIlYJUiS66j6a2E9zmJdtU4iP4Z1wKzGYWc-6V5iB0S0lK48x3hzGljFN-hqY0K_KECZGfoymhnCRlKbIJuvJ-RwjJBKWXaMIEz2Ukp-hr_Q6uAzXsbW-CVR4PNW4cjHZ00IcHDNib1qhgDwYv1pjj0Q0-QNNCr22P18sFZtgZZcYwOBwj0Ay99cdkHYyLx66Z7xs8OGjjWWObHlIMurNHykGwQ-9xbFIQ_DW6qKH15uZ3z9DmebF5eklWb8vXp8dVomRZJDU1WhApVS4UJUpxgJzmhkvJpC45J7Iw28xopmtgUG5zJZkAmYExqiSiyGbo_lSr4i_emboane3AfVaUVEejVTRa_RiN7N2JHT-2ndH_5J_C7BvtLXKX</recordid><startdate>201712</startdate><enddate>201712</enddate><creator>Lebkowska-Wieruszewska, B</creator><creator>De Vito, V</creator><creator>Owen, H</creator><creator>Poapholatep, A</creator><creator>Giorgi, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-3657-4703</orcidid></search><sort><creationdate>201712</creationdate><title>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</title><author>Lebkowska-Wieruszewska, B ; De Vito, V ; Owen, H ; Poapholatep, A ; Giorgi, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c976-f1ed8099c58c10cc4aa515e49929d744096eb3ed2dfa2a7b5c928a93aeec70863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Cats</topic><topic>Cross-Over Studies</topic><topic>Injections, Intravenous - veterinary</topic><topic>Male</topic><topic>Receptors, Prostaglandin E, EP4 Subtype - antagonists & inhibitors</topic><topic>Sulfonylurea Compounds - administration & dosage</topic><topic>Sulfonylurea Compounds - blood</topic><topic>Sulfonylurea Compounds - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lebkowska-Wieruszewska, B</creatorcontrib><creatorcontrib>De Vito, V</creatorcontrib><creatorcontrib>Owen, H</creatorcontrib><creatorcontrib>Poapholatep, A</creatorcontrib><creatorcontrib>Giorgi, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lebkowska-Wieruszewska, B</au><au>De Vito, V</au><au>Owen, H</au><au>Poapholatep, A</au><au>Giorgi, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats</atitle><jtitle>Journal of veterinary pharmacology and therapeutics</jtitle><addtitle>J Vet Pharmacol Ther</addtitle><date>2017-12</date><risdate>2017</risdate><volume>40</volume><issue>6</issue><spage>e11</spage><pages>e11-</pages><issn>0140-7783</issn><eissn>1365-2885</eissn><abstract>Drugs that provide effective analgesia in cats are limited. The aim of the study was to assess the pharmacokinetics of grapiprant after 2 mg/kg administration via p.o. and i.v. routes in cats. Six healthy adult cats were used according to an open, single-dose, two-treatment, two-period, randomized cross-over design. Cats were assigned to two treatment groups and administered with 2 mg/kg of grapiprant (pure powder) through p.o. and i.v. administration. Blood samples were collected at preassigned times and analysed by a validated HPLC method. After both administrations, grapiprant concentrations were detectable in plasma for up to 24 hr in five of six animals. The critical parameters including clearance (173.2 ml hr
kg
, range 120-326 ml hr
kg
) and volume of distribution (918 ml/kg, range 611-1608 ml/kg) were calculated from the i.v. group. The mean oral F% was low (39.6% range 31.5%-45.2%). If the assumption that the minimal effective concentration in dogs (164 ng/ml) applies in cats too, grapiprant orally administered at 2 mg/kg might be effective for 10 hr. Further studies are necessary to establish the minimal effective concentration in this animal species.</abstract><cop>England</cop><pmid>28459136</pmid><doi>10.1111/jvp.12414</doi><orcidid>https://orcid.org/0000-0003-3657-4703</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0140-7783 |
ispartof | Journal of veterinary pharmacology and therapeutics, 2017-12, Vol.40 (6), p.e11 |
issn | 0140-7783 1365-2885 |
language | eng |
recordid | cdi_crossref_primary_10_1111_jvp_12414 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Administration, Oral Animals Cats Cross-Over Studies Injections, Intravenous - veterinary Male Receptors, Prostaglandin E, EP4 Subtype - antagonists & inhibitors Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - blood Sulfonylurea Compounds - pharmacokinetics |
title | Pharmacokinetics of grapiprant, a selective EP 4 prostaglandin PGE 2 receptor antagonist, after 2 mg/kg oral and i.v. administrations in cats |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T00%3A42%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20grapiprant,%20a%20selective%20EP%204%20prostaglandin%20PGE%202%20receptor%20antagonist,%20after%202%20mg/kg%20oral%20and%20i.v.%20administrations%20in%20cats&rft.jtitle=Journal%20of%20veterinary%20pharmacology%20and%20therapeutics&rft.au=Lebkowska-Wieruszewska,%20B&rft.date=2017-12&rft.volume=40&rft.issue=6&rft.spage=e11&rft.pages=e11-&rft.issn=0140-7783&rft.eissn=1365-2885&rft_id=info:doi/10.1111/jvp.12414&rft_dat=%3Cpubmed_cross%3E28459136%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28459136&rfr_iscdi=true |